AKBETA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AKBETA (AKBETA).
AKBETA is not a recognized drug; please verify the drug name.
| Metabolism | Unknown |
| Excretion | Renal excretion accounts for 80-85% of the dose, primarily as unchanged drug; biliary/fecal elimination is 10-15%. |
| Half-life | Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 10-20 hours in severe renal impairment. |
| Protein binding | 60-70% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is 1.0-2.0 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 50-60% due to first-pass hepatic metabolism; IV: 100%. |
| Onset of Action | IV: 5-10 minutes; Oral: 30-60 minutes (peak effect 1-2 hours). |
| Duration of Action | IV: 2-4 hours; Oral: 4-6 hours (shorter in tachycardia, longer in renal impairment). |
Metoprolol tartrate: 50-100 mg orally twice daily; metoprolol succinate: 25-200 mg orally once daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; in severe renal impairment (GFR < 10 mL/min), administer with caution. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | 1-2 mg/kg per day orally in divided doses; maximum 200 mg/day. |
| Geriatric use | Initiate at lower end of dosing range (e.g., 25 mg once daily for metoprolol succinate), titrate slowly due to increased risk of bradycardia and hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AKBETA (AKBETA).
| Breastfeeding | Atenolol is excreted in breast milk with a high M/P ratio of approximately 4.6. Peak milk levels occur 2-4 hours after dose. Due to potential for infant bradycardia and hypoglycemia, use is not recommended; if used, monitor infant for signs of beta-blockade. |
| Teratogenic Risk | Pregnancy category D. First trimester: Associated with fetal bradycardia, hypoglycemia, and growth restriction; beta-blocker exposure increases risk of low birth weight. Second trimester: Continued risk of fetal bradycardia and growth restriction; may cause placental hypoperfusion. Third trimester: Risk of neonatal hypoglycemia, bradycardia, and respiratory depression; beta-blockade may attenuate fetal heart rate response to distress. |
■ FDA Black Box Warning
No boxed warning applicable
| Serious Effects |
["No contraindications identified"]
| Precautions | ["No warnings due to lack of data"] |
| Food/Dietary | No significant food interactions. Taking with meals may reduce gastrointestinal irritation. Avoid excessive salt intake as it may exacerbate Meniere's symptoms. |
| Clinical Pearls | AKBETA (betahistine) is primarily used for Meniere's disease. Titrate dose gradually to minimize GI upset. Avoid in patients with pheochromocytoma or severe asthma. Monitor for hypotension and bradycardia. Efficacy may take weeks to manifest. |
Loading safety data…
| Fetal Monitoring | Maternal: Heart rate, blood pressure, signs of bronchospasm, blood glucose, and renal function. Fetal: Ultrasound for growth and amniotic fluid volume, fetal heart rate monitoring during labor. Neonatal: Observe for bradycardia, hypoglycemia, and respiratory depression for 48–72 hours postpartum. |
| Fertility Effects | No known adverse effects on fertility in either sex. Beta-blockers generally do not impair fertility, but may rarely cause erectile dysfunction or ejaculatory disorders in males. |
| Patient Advice | Take with or after meals to reduce stomach upset. · Do not drive or operate machinery if you experience dizziness or drowsiness. · Report any worsening of asthma symptoms or irregular heartbeat. · Avoid alcohol as it may increase side effects like dizziness. · Store at room temperature away from moisture and heat. |